1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Aligos’s MASH Data Look Competitive, But Path Forward Is Unclear

 
• By Joseph Haas

Aligos’s THRβ agonist yielded hepatic fat reduction equal to or better than its class, but the biotech prefers moving forward with a partner. Hepatitis B may be the firm’s higher priority.

Fatty liver disease
Aligos's MASH candidate showed liver fat reduction ability in Phase IIa • Source: Shutterstock

Aligos Therapeutics, Inc. may be able to improve on the safety and efficacy for the first drug approved for non-alcoholic/metabolic dysfunction-associated steatohepatitis (NASH/MASH), Madrigal Pharmaceuticals, Inc.’s Rezdiffra (resmetirom), based on Phase IIa data for its THRβ agonist ALG-055009, but Aligos is seeking a partner to advance its drug.

Aligos also has a first-in-class Phase Ib candidate aimed at viral suppression of chronic hepatitis B that is competing for the company’s resources. CEO Lawrence Blatt told Scrip he “loves...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

More from R&D